ImmunoGen T-DM1 data positive, says Roth Capital

After Immunogen (IMGN) and Roche (RHHBY) reported significantly improved overall survival data from the T-DM1 in 2nd line metastatic breast cancer, Roth Capital believes the improvement should facilitate a more rapid sales ramp after the drug's approval. The firm expects the drug to obtain FDA approval in 1H13 and it maintains a $19 target and Buy rating on Immunogen.